A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.
CD1d presentation of alpha-galactosyl ceramides to natural killer T cells has been a focal point of the study of regulatory T cells. KRN7000, an alpha-galactosyl ceramide originally generated from structure activity studies of antitumor properties of marine sponge glycolipids, is currently the most commonly used agonist ligand and is used to stain NKT cells. However, this glycolipid suffers from poor solubility and availability. We have developed an alpha-galactosyl ceramide with improved solubility over KRN7000 that effectively stains NKT cells, both mouse and human, and stimulates cytokine release at low concentrations.
Liu
Yang
Y
Brigham Young University, Provo, UT 84602, USA.
Goff
Randal D
RD
Zhou
Dapeng
D
Mattner
Jochen
J
Sullivan
Barbara A
BA
Khurana
Archana
A
Cantu
Carlos
C
Ravkov
Eugene V
EV
Ibegbu
Chris C
CC
Altman
John D
JD
Teyton
Luc
L
Bendelac
Albert
A
Savage
Paul B
PB
D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D018949:Antigens, CD1 / Q000276:immunology; D055610:Antigens, CD1d; D016207:Cytokines / Q000378:metabolism; D005699:Galactosylceramides / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D006825:Hybridomas / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D013194:Staining and Labeling; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology
D000276:Adjuvants, Immunologic; D018949:Antigens, CD1; D055610:Antigens, CD1d; C526877:CD1D protein, human; D016207:Cytokines; D005699:Galactosylceramides; C512575:PBS 57; C103873:KRN 7000